Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT03775746

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
East and North Hertfordshire NHS Trust (from the registry)
Registry
  • NCT NCT03775746
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03775746. Randomized; no masking; primary purpose treatment. Start 2019-01-08 (actual); primary completion 2021-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
Acronym
VaLiDate-R
Condition
Acute Coronary Syndrome
Intervention (Drug)
Clopidogrel 75Mg Tablet
Intervention (Drug)
Rivaroxaban 2.5Mg Tablet
Intervention (Drug)
Ticagrelor 90Mg Tablet
Lead sponsor
East and North Hertfordshire NHS Trust (class: other government)
Collaborator
University of Hertfordshire (class: other)

Record details

Record id
cardio:ct-nct03775746
Content hash
3323d7a9c220446786276d5e635dc56ff0d75a296181af6344048b6fc2fbe6e4